(Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03381261|
Recruitment Status : Unknown
Verified March 2019 by William Gerald Austen, Massachusetts General Hospital.
Recruitment status was: Recruiting
First Posted : December 21, 2017
Last Update Posted : March 19, 2019
|Condition or disease||Intervention/treatment||Phase|
|Migraine||Drug: Botulinum toxin type A||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Novel Concepts for OnabotulinumtoxinA (Botox) Mechanisms of Action: Role in Altering the Molecular Environment in Which Pain Fibers Exist|
|Actual Study Start Date :||December 1, 2017|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||August 2020|
Experimental: Botulinum toxin type A injection arm
All patients will be injected with Botulinum toxin on one side of the back of the head.
Drug: Botulinum toxin type A
Injection of Botulinum toxin type A in back of head
Other Name: Botox
- molecular markers in discarded tissue of migraine patients [ Time Frame: one year ]molecular markers in discarded tissue of migraine surgery will be analyzed. Gene Expression CodeSet profiling 594 genes; 579 immunology-related human genes + 15 internal reference controls.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03381261
|Contact: William G Austenfirstname.lastname@example.org|
|Contact: Lisa Gfrereremail@example.com|
|Principal Investigator:||William G. Austen, MD||Massachusetts General Hospital|